Posted by Michael Wonder on 23 Nov 2020
BeiGene announces the approval of Xgeva (denosumab) in China for the prevention of skeletal-related events in patients with bone metastases from solid tumours and in patients with multiple myeloma
19 November 2020 - BeiGene today announced that the China NMPA has approved Xgeva (denosumab) for the prevention of skeletal-related events in patients with bone metastases from solid tumours and in patients with multiple myeloma.
Developed by Amgen and licensed to BeiGene in China under a strategic collaboration commenced earlier this year, Xgeva is also approved and marketed in China for the treatment of adults and skeletally mature adolescents with giant cell tumour of the bone that is unresectable or where surgical resection is likely to result in severe morbidity.
